Trimunocor Ltd Information

Developing ground-breaking solutions in the fight against neonatal chronic lung disease. Half of premature babies under 26 weeks develop neonatal chronic lung disease. This is a debilitating disease and there are no effective treatments to prevent it. These babies are deficient in the natural anti-inflammatory/anti-infective protein, surfactant protein D (SP-D). This protein is lacking in the current therapies. However, we have developed a novel way to produce the functional part of this natural defence protein. Having extensive pre-clinical efficacy data demonstrating the treatment of replacing this deficient protien, using an 'Aid for Start up' Innovate grant we are currently developing a GMC manufacturing procedure and preparing for clinical trials.